CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Abstract
Immune checkpoint inhibitors (ICI) have shown clinical benefit in many types of metastatic cancers with only a few predictive biomarkers identified so far. CDKN2A is commonly altered in human cancers, but prior studies have provided conflicting evidence regarding the association between CDKN2A genomic alterations (GA) and response to ICIs. Herein, we examined the impact of loss-of-function CDKN2A alterations on response and survival in patients treated with ICIs.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-0575
Entities
People
- Alexander Gusev
- Amin H Nassar
- David A Braun
- David J Kwiatkowski
- Elie W. Akl
- Elio Adib
- F Stephen Hodi
- Guru Sonpavde
- Kent W. Mouw
- Marios Giannakis
- Pier Vitale Nuzzo
- Robert I. Haddad
- Sachet A Shukla
- Sarah Abou Alaiwi
- Tarek H Mouhieddine
- Toni K Choueiri
Organizations
- Brigham and Women's Hospital
- Dana–Farber Cancer Institute
- Harvard Medical School
- Icahn School of Medicine at Mount Sinai
- National Cancer Institute
- United States Department of Defense
- University of Genoa